SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Impact · against what's priced in

The long-term clinical and endoscopic data for Skyrizi and Rinvoq in IBD provides supporting evidence for current growth expectations but lacks the novelty to drive a price catalyst. Because the market already assumes these two drugs will successfully replace Humira's revenue, these results are largely confirmatory.

ABBV+0.05: Already priced in
The price assumes: SKYRIZI and RINVOQ replacing HUMIRA's lost revenue

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

How each ticker is affected

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

How each ticker is affected

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Track these names every morning.

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

Defiance CEO on Motivation Behind First Autism ETF

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

How each ticker is affected

Next reads from the same story arc

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

How each ticker is affected

Next reads from the same story arc

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Track these names every morning.

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

Defiance CEO on Motivation Behind First Autism ETF

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income